ArticleOpen forum infectious diseases2021
Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in
Article in Open forum infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 38 citations in OpenAlex.
- Clostridioides difficile pathogenesis and control.Nature reviews. Microbiology · 2026Review
- Reversion of heme-dependent metronidazole resistance inMicrobiology spectrum · 2026Article
- EmergingEmerging microbes & infections · 2025Article
- Experimental glycopeptide antibiotic EVG7 prevents recurrent Clostridioides difficile infection by sparing members of the Lachnospiraceae family.Nature communications · 2025Article
- Abundant geographical divergence of Clostridioides difficile infection in China: a prospective multicenter cross-sectional study.BMC infectious diseases · 2025Article
- Comparative effectiveness of metronidazole and vancomycin for treatment ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Antimicrobial susceptibility inJAC-antimicrobial resistance · 2024Article
- Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains ofAntimicrobial agents and chemotherapy · 2024Article
- Article
- The management ofMedicine and pharmacy reports · 2024Review
- Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.PloS one · 2024Article
- Antibiotic Resistances of Clostridioides difficile.Advances in experimental medicine and biology · 2024Article
- Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile.Nature communications · 2023Article
- Surveillance of Clostridioides difficile Antimicrobial Resistance in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Reply to Gonzales-Luna et al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Reference Susceptibility Testing and Genomic Surveillance of Clostridioides difficile, United States, 2012-17.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Non-ToxigenicAntibiotics (Basel, Switzerland) · 2023Article
- Controversies in the Prevention and Treatment ofMicroorganisms · 2023Review
- Iron Effects onAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundClinical studies have demonstrated inferior cure rates when metronidazole (MTZ) is used to treat
methodsThis multicenter cohort study included adults diagnosed with CDI between 2017 and 2018.
resultsOf the 356 patients included, 72% received MTZ-based therapy and 27% experienced initial clinical failure. CART analysis identified an MTZ MIC ≥1 µg/mL above which patients had a higher rate of initial clinical failure. MTZ MICs ranged from 0.25 to 8 µg/mL (MIC
conclusionsUsing a reproducible method to determine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.